Menu Search
Close Search

MoST-LLy

 
MOLECULAR SCREENING AND THERAPEUTICS IN LEUKAEMIA AND LYMPHOMA

(MoST-LLy)

 

The current  MoST-LLy study is due to close to recruitment 13 December 2024 and a new MoST-LLy study led by QIMR Berghofer is due to open in 2025.

QIMR Berghofer is now a national remote consenting hub for the MoST-LLy study extending access for patients to all parts of Australia.

 

ABOUT THIS STUDY

The Molecular Screening and Therapeutics (MoST) Program is a clinical research program that is testing a new approach to providing treatments for patients with cancer. MoST-LLy is a cohort within MoST that is just for patients with blood cancers. The MoST program personalises experimental treatment based on an individual’s unique cancer genetic profile, rather than where their cancer originates.

If a patient is suitable for the program, their blood cancer is tested to see if the DNA contains genetic biomarkers that can guide treatment. This process is called molecular screening or genetic testing. After a patient’s blood cancer is tested, a report is sent to their referring haematologist with information on (i) any genetic biomarkers that were identified and (ii) the types of treatment that may be suitable.

For further information about this program see also Understanding the Blood Cancer Genomics Trial (video posted by the Leukaemia Foundation (Australia))

 

ELIGIBILITY

  • Patients with advanced or poor-prognosis blood cancer of any type
  • Patients aged 18 years and over
  • Patients with limited treatment options, or who are receiving their last line of standard therapy
 
 
QUESTIONS?

If you would like to contact us about this study you can email us at: mostlly@qimrberghofer.edu.au

 

HOW TO PARTICIPATE

Patients are asked to discuss the program with their doctor or treating haematologist who may refer a patient they consider suitable by filling in the online referral and attaching a pathology report.

The MoST-LLy General Information Sheet provides a summary of this process.

 

STUDY CONTACT DETAILS

T: 07 3845 3678

E: mostlly@qimrberghofer.edu.au

 

ADDITIONAL INFORMATION

The MoST-LLy research program is a collaboration between QIMR Berghofer, led by Professor Steven Lane, Group leader of The Gordon and Jessie Gilmour Leukaemia Research Laboratory at QIMR Berghofer and clinical haematologist at Royal Brisbane and Women’s Hospital, the Garvan Institute of Medical Research, SA Pathology, PathWest, Omico (the Australian Genomic Cancer Medicine Centre) and the NHMRC Clinical Trials Centre at the University of Sydney. This program has ethics approval from St Vincent’s Hospital Human Research Ethics Committee (2019/ETH03114) and the University of Sydney is the regulatory sponsor of clinical trials undertaken through the program. MoST-LLy has generously been co-funded by The Leukemia Foundation, Tour de Cure and the Medical Research Future Fund (MRFF).

Further information can be found following external links: